Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 4/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LSS | P48449 | 1/20 | 0.34 |
| ▸ | PRLHR | P49683 | 3/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | GIPR | P48546 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24483837 | 0.94 | GCGR (0.38) | GCGRTRPV1POLBMAPTLSS | |
| SCHEMBL22845294 | 0.91 | PRLHR (0.37) | GCGRTRPV1POLBMAPTLSS | |
| SCHEMBL26842628 | 0.90 | HTR1A (0.34) | POLBMAPTSLC6A4HRH3 | |
| SCHEMBL22845199 | 0.89 | LMNA (0.37) | POLBMAPT | |
| SCHEMBL22845275 | 0.87 | AR (0.36) | — | |
| SCHEMBL22845221 | 0.86 | GCGR (0.40) | GCGRPOLBMAPTSCN9AGIPR | |
| SCHEMBL22845448 | 0.86 | MAPT (0.39) | POLBMAPT | |
| SCHEMBL24173968 | 0.85 | PRLHR (0.36) | GCGRPOLBMAPTLSSPRLHR | |
| SCHEMBL22845309 | 0.85 | MAPK14 (0.34) | MAPT | |
| SCHEMBL22845209 | 0.84 | MAPT (0.42) | POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | GCGR 1314/4885TRPV1 204/4885POLB 3198/4885 |
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | GCGR 1314/4885TRPV1 204/4885POLB 3198/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | GCGR 1314/4885TRPV1 204/4885POLB 3198/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | GCGR 1314/4885TRPV1 204/4885POLB 3198/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | GCGR 1314/4885TRPV1 204/4885POLB 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.